GlassScriptPhysician profile
Shandra Tyus
NPI 1891296695
$3,430.47
in general payments reported to CMS, 2019-2025
25 companies · $90.39 in 2025
The $90.39 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,687 · 2022: $958 · 2023: $659 · 2024: $36.32 · 2025: $90.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.39 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $330.70 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $298.46 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $240.90 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $240.64 | 2021-2023 | Qelbree |
| Alkermes, INC. | $218.88 | 2022-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $185.49 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $182.65 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $177.16 | 2021-2023 | Spravato |
| Vanda Pharmaceuticals INC. | $147.57 | 2021-2022 | |
| Bausch Health US, LLC | $80.59 | 2021 | |
| Lundbeck LLC | $76.27 | 2021-2023 | Rexulti |
| Noven Therapeutics, LLC | $65.34 | 2021-2022 | |
| Tris Pharma INC | $55.03 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $50.33 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $40.43 | 2021 | |
| Merck Sharp & Dohme LLC | $31.94 | 2021 | |
| Corium, LLC | $30.44 | 2022 | |
| Almatica Pharma LLC | $29.34 | 2022-2023 | Gralise |
| E.R. Squibb & Sons, L.L.C. | $28.67 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $26.56 | 2021-2023 | Austedo |
| Axsome Therapeutics, INC. | $23.78 | 2023 | Auvelity |
| Eisai INC. | $18.65 | 2022 | |
| Adlon Therapeutics L.P. | $13.37 | 2021 | |
| Neos Therapeutics, LP | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shandra Tyus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.